Core Insights - The company, Xiansheng Pharmaceutical, plans to acquire all assets of Shanghai Xiangrui and all shares of Xianwei for a total consideration of 83.1838 million yuan, with specific amounts of 17.5226 million yuan and 65.6612 million yuan respectively [1] - The acquisition aims to quickly enter the mRNA technology field, which is a revolutionary breakthrough in biomedicine, allowing for high immunogenicity and safety, with a shorter production cycle compared to traditional vaccines [2] Group 1 - The main assets of Shanghai Xiangrui include laboratory instruments and office equipment, while Xianwei's assets consist of raw materials for medical consumables, various medical devices, and a nearly completed mRNA factory awaiting GMP certification [1] - The mRNA technology platform established by Shanghai Xiangrui and Xianwei enables the company to respond flexibly to diverse future demands in infectious diseases, cancer treatment, autoimmune diseases, rare diseases, and gene editing [2] - The strategic acquisition is expected to enhance the company's competitive advantage in key areas such as infectious diseases, cancer, and autoimmune diseases, complementing its existing innovative drug pipeline [2] Group 2 - The acquisition will facilitate the rapid integration of key technologies, clinical data, and production resources, thereby improving research and development efficiency and shortening the new drug development cycle [2] - This strategic move is also aimed at eliminating potential competitive risks and establishing a solid barrier in the mRNA sector [2]
先声药业(02096)拟8318.38万元收购上海祥瑞的全部资产及先为的全部股权 以快速切入mRNA技术领域